Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,103 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02323113 | Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 43 | Calithera Biosciences, IncINDUSTRY | 2 | Feb 8, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT00887926 | Study of IMC-EB10 in Participant With Leukemia | terminated | Phase 1 | 25 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT04402723 | Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML | terminated | Phase 1 | 8 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT04866056 | Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. | terminated | Phase 1 / Phase 2 | 1 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03214666 | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | terminated | Phase 1 / Phase 2 | 12 | GT Biopharma, Inc.INDUSTRY | 1 | Nov 10, 2022 | clinicaltrials |
| NCT04496999 | HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.(HDMM) | terminated | Phase 1 | 2 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03516760 | Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia | terminated | Phase 1 | 36 | AvenCell Europe GmbHINDUSTRY | 1 | Sep 29, 2022 | clinicaltrials |
| NCT03218683 | Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. | terminated | Phase 1 | 70 | AstraZenecaINDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT02267863 | A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS | terminated | Phase 1 | 21 | Aptose Biosciences Inc.INDUSTRY | 1 | Aug 22, 2022 | clinicaltrials |
| NCT03760666 | A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 17 | Clear Creek Bio, Inc.INDUSTRY | 1 | Aug 8, 2022 | clinicaltrials |
| NCT02773732 | Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101) | terminated | Phase 1 / Phase 2 | 11 | University of FloridaOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT01014546 | Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | terminated | Phase 1 | 5 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT01550185 | Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 10 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT05001451 | Study of GDX012 in Patients With MRD Positive AML | terminated | Phase 1 | 3 | GammaDelta Therapeutics LimitedINDUSTRY | 1 | Jul 20, 2022 | clinicaltrials |
| NCT01640301 | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 47 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 14, 2022 | clinicaltrials |
| NCT04006847 | Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 1 | Milton S. Hershey Medical CenterOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT02452983 | Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome(SS1) | terminated | Phase 1 | 14 | Gustavo RiveroOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT03552029 | Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 10 | Daiichi SankyoINDUSTRY | 1 | May 20, 2022 | clinicaltrials |
| NCT03217838 | Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. | terminated | Phase 1 | 50 | AstraZenecaINDUSTRY | 2 | Apr 5, 2022 | clinicaltrials |
| NCT01187810 | Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL | terminated | Phase 1 | 3 | South Plains Oncology ConsortiumNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
| NCT01876953 | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03696537 | IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT | terminated | Phase 1 | 6 | Naoyuki G. Saito, M.D., Ph.D.OTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT03922477 | A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 13 | Hoffmann-La RocheINDUSTRY | 1 | Feb 21, 2022 | clinicaltrials |
| NCT03761069 | Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias | terminated | Phase 1 | 33 | PTC TherapeuticsINDUSTRY | 1 | Feb 2, 2022 | clinicaltrials |
| NCT04097301 | Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | terminated | Phase 1 / Phase 2 | 8 | AGC Biologics S.p.A.INDUSTRY | 2 | Jan 19, 2022 | clinicaltrials |
| NCT03797261 | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies | terminated | Phase 1 | 9 | AbbVieINDUSTRY | 3 | Dec 7, 2021 | clinicaltrials |
| NCT03519984 | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia | terminated | Phase 1 | 3 | University of Southern CaliforniaOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT02795520 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 32 | OncoTherapy Science, Inc.INDUSTRY | 1 | Nov 24, 2021 | clinicaltrials |
| NCT02078960 | A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study) | terminated | Phase 1 / Phase 2 | 10 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 4 | Nov 9, 2021 | clinicaltrials |
| NCT02770820 | Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 9 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 29, 2021 | clinicaltrials |
| NCT02319369 | Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | terminated | Phase 1 | 74 | Daiichi SankyoINDUSTRY | 1 | Oct 11, 2021 | clinicaltrials |
| NCT03588936 | Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant | terminated | Phase 1 | 2 | Medical College of WisconsinOTHER | 1 | Oct 11, 2021 | clinicaltrials |
| NCT01663766 | Phase I Study of Milatuzumab for Graft Versus Host Disease | terminated | Phase 1 | 12 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT01113502 | Eltrombopag in Elderly Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 44 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT02440568 | AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients | terminated | Phase 1 / Phase 2 | 22 | University of Illinois at ChicagoOTHER | 1 | Jul 6, 2021 | clinicaltrials |
| NCT01486784 | A Phase I-II Open Label Non-Randomized Study Using TL32711 for Patients With Acute Myelogenous Leukemia, Myelodysplastic Syndrome and Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 27 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT03125876 | A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 12 | Sunshine Lake Pharma Co., Ltd.INDUSTRY | 1 | Mar 24, 2021 | clinicaltrials |
| NCT03360006 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer | terminated | Phase 1 | 30 | AbbVieINDUSTRY | 1 | Mar 24, 2021 | clinicaltrials |
| NCT03113071 | Safety and Activity of Digoxin With Decitabine in Adult AML and MDS | terminated | Phase 1 / Phase 2 | 1 | Fox Chase Cancer CenterOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT01643603 | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies | terminated | Phase 1 | 5 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | terminated | Phase 1 | 20 | Tarix PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT02782403 | Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT01656252 | Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission(PrE0901) | terminated | Phase 1 / Phase 2 | 15 | PrECOG, LLC.OTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT02953561 | Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02750254 | Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation | terminated | Phase 1 | 5 | Washington University School of MedicineOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT00674427 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant | terminated | Phase 1 | 13 | University of PennsylvaniaOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT00234000 | Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes | terminated | Phase 1 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Feb 8, 2023source: clinicaltrials